Drugs / Bacillus clausil spores
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06449508 Comparator | Jul 2024 → Jun 2025 | congenital nonhemolytic jaundice | Tanta University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus clausil spores | “will receive 5 drops of probiotic supplement containing Bacillus clausil spores (Enterogermania amp 2 billion/5 mL) once daily plus phototherapy till discharge.” NCT06449508 ↗ |
| Known as | Enterogermania | “will receive 5 drops of probiotic supplement containing Bacillus clausil spores (Enterogermania amp 2 billion/5 mL) once daily plus phototherapy till discharge.” NCT06449508 ↗ |
| Modality | Other / unclassified | “drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )” NCT06449508 ↗ |